CN120267666A - 利福布汀治疗方法、用途和组合物 - Google Patents

利福布汀治疗方法、用途和组合物 Download PDF

Info

Publication number
CN120267666A
CN120267666A CN202510450433.5A CN202510450433A CN120267666A CN 120267666 A CN120267666 A CN 120267666A CN 202510450433 A CN202510450433 A CN 202510450433A CN 120267666 A CN120267666 A CN 120267666A
Authority
CN
China
Prior art keywords
rifabutin
acid
solution
formulation
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202510450433.5A
Other languages
English (en)
Chinese (zh)
Inventor
S·洛基乌罗
S·比昂迪
G·E·戴尔
M·布罗特
M·吉特青格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioversys AG
Original Assignee
Bioversys AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioversys AG filed Critical Bioversys AG
Publication of CN120267666A publication Critical patent/CN120267666A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202510450433.5A 2019-09-12 2020-08-03 利福布汀治疗方法、用途和组合物 Pending CN120267666A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201962899257P 2019-09-12 2019-09-12
US62/899,257 2019-09-12
US201962902019P 2019-09-18 2019-09-18
US62/902,019 2019-09-18
US201962941160P 2019-11-27 2019-11-27
US62/941,160 2019-11-27
CN202080005144.XA CN113015519B (zh) 2019-09-12 2020-08-03 利福布汀治疗方法、用途和组合物
PCT/IB2020/000648 WO2021048612A1 (en) 2019-09-12 2020-08-03 Rifabutin treatment methods, uses, and compositions

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080005144.XA Division CN113015519B (zh) 2019-09-12 2020-08-03 利福布汀治疗方法、用途和组合物

Publications (1)

Publication Number Publication Date
CN120267666A true CN120267666A (zh) 2025-07-08

Family

ID=72428294

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202510450433.5A Pending CN120267666A (zh) 2019-09-12 2020-08-03 利福布汀治疗方法、用途和组合物
CN202080005144.XA Active CN113015519B (zh) 2019-09-12 2020-08-03 利福布汀治疗方法、用途和组合物
CN202510450436.9A Pending CN120267667A (zh) 2019-09-12 2020-08-03 利福布汀治疗方法、用途和组合物
CN202510450439.2A Pending CN120267668A (zh) 2019-09-12 2020-08-03 利福布汀治疗方法、用途和组合物

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN202080005144.XA Active CN113015519B (zh) 2019-09-12 2020-08-03 利福布汀治疗方法、用途和组合物
CN202510450436.9A Pending CN120267667A (zh) 2019-09-12 2020-08-03 利福布汀治疗方法、用途和组合物
CN202510450439.2A Pending CN120267668A (zh) 2019-09-12 2020-08-03 利福布汀治疗方法、用途和组合物

Country Status (23)

Country Link
US (1) US12370184B2 (enExample)
EP (1) EP4027976B1 (enExample)
JP (2) JP7777518B2 (enExample)
KR (1) KR20220103697A (enExample)
CN (4) CN120267666A (enExample)
AU (2) AU2020346414B2 (enExample)
BR (1) BR112022004659A2 (enExample)
CA (1) CA3154318A1 (enExample)
DK (1) DK4027976T3 (enExample)
ES (1) ES3056897T3 (enExample)
FI (1) FI4027976T3 (enExample)
HR (1) HRP20251645T1 (enExample)
LT (1) LT4027976T (enExample)
MX (1) MX2022003075A (enExample)
MY (1) MY210244A (enExample)
PH (1) PH12022550606A1 (enExample)
PL (1) PL4027976T3 (enExample)
PT (1) PT4027976T (enExample)
RS (1) RS67627B1 (enExample)
SI (1) SI4027976T1 (enExample)
SM (1) SMT202500491T1 (enExample)
WO (1) WO2021048612A1 (enExample)
ZA (1) ZA202203357B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230364065A1 (en) * 2022-05-16 2023-11-16 BioVersys AG Antibiotic combination therapies
WO2026022215A1 (en) * 2024-07-23 2026-01-29 BioVersys AG Lyophilized formulations of rifabutin

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645508B1 (en) 1999-06-18 2003-11-11 Jivn-Ren Chen Stable L-ascorbic acid composition
CN1775214A (zh) * 2005-11-18 2006-05-24 武汉大学 利福喷丁、利福平、利福布丁或利福定注射剂及其制备方法
AU2007229275B2 (en) * 2006-03-23 2013-02-07 Agriculture Victoria Services Pty Ltd Antimicrobial protein
CN101362067A (zh) 2007-08-06 2009-02-11 天津科技大学 一种微胶囊制备方法
MY158809A (en) * 2010-09-22 2016-11-15 Craun Res Sdn Bhd Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same
EA016410B1 (ru) * 2010-11-13 2012-04-30 Ооо "Нпк Наносистема" Фармацевтическая композиция на основе наночастиц циклодекстрина, содержащих рифабутин, способ ее получения, способ лечения микобактериоза и геликобактерной инфекции (варианты)
EP2670417A4 (en) 2011-01-31 2014-07-09 Us Army METHOD AND COMPOSITIONS FOR TREATING BACTERIAL INFECTIONS WITH IRON RADIATORS
CN102178604B (zh) * 2011-03-22 2014-03-05 中国人民解放军第三0九医院 凝胶微球制备装置、方法及可注射抗结核药物凝胶微球
WO2015104668A2 (en) * 2014-01-09 2015-07-16 Camus Pharma Pvt. Ltd. Lyophilized formulations for parenteral use
JP6867288B2 (ja) * 2014-07-21 2021-04-28 エーエムディー セラピューティックス エルエルシー リファマイシンの眼科用組成物およびその使用
US9763996B2 (en) 2015-01-16 2017-09-19 Northern Antibiotics, Ltd. Polymyxin derivative and uses thereof
WO2016178240A1 (en) * 2015-05-04 2016-11-10 Gufic Biosciences Limited A freeze dried pharmaceutical formulation of rifabutin and process for preparation thereof
AU2018219149A1 (en) 2017-02-07 2019-09-19 Unm Rainforest Innovations Isotope enhanced ambroxol for long lasting autophagy induction
US11701346B2 (en) 2018-11-28 2023-07-18 University Of Southern California Rifabutin for the treatment of acinetobacter baumannii

Also Published As

Publication number Publication date
SMT202500491T1 (it) 2026-03-09
MY210244A (en) 2025-09-04
SI4027976T1 (sl) 2026-02-27
DK4027976T3 (da) 2025-12-22
CN120267668A (zh) 2025-07-08
LT4027976T (lt) 2026-01-12
JP2022548858A (ja) 2022-11-22
MX2022003075A (es) 2022-07-11
CN120267667A (zh) 2025-07-08
RS67627B1 (sr) 2026-02-27
US20240000759A1 (en) 2024-01-04
AU2020346414A1 (en) 2022-04-14
AU2020346414B2 (en) 2025-10-02
CN113015519A (zh) 2021-06-22
EP4027976A1 (en) 2022-07-20
CA3154318A1 (en) 2021-03-18
EP4027976B1 (en) 2025-10-01
CN113015519B (zh) 2025-03-28
HRP20251645T1 (hr) 2026-02-13
ZA202203357B (en) 2023-12-20
ES3056897T3 (en) 2026-02-25
PT4027976T (pt) 2025-12-23
PH12022550606A1 (en) 2023-01-23
KR20220103697A (ko) 2022-07-22
PL4027976T3 (pl) 2026-02-16
WO2021048612A1 (en) 2021-03-18
FI4027976T3 (fi) 2025-12-12
US12370184B2 (en) 2025-07-29
AU2025283482A1 (en) 2026-01-15
JP7777518B2 (ja) 2025-11-28
BR112022004659A2 (pt) 2022-06-21
JP2026027477A (ja) 2026-02-18

Similar Documents

Publication Publication Date Title
US20250360115A1 (en) Rifabutin treatment methods, uses, and compositions
CN110279698B (zh) 头孢特咯瓒抗生素组合物
JP2026027477A (ja) リファブチンの処置方法、使用および組成物
HK1214148A1 (zh) 用於治疗中枢介导的恶心及呕吐的组合物及方法
CN102781447B (zh) 用于治疗过度增生性疾病、自身免疫性疾病和心脏病的包含3-奎宁环酮衍生物的水溶液
JP2002504524A (ja) オキサリプラチン溶液組成物
CN107810000B (zh) 来氟米林的可注射药物组合物
KR20020059592A (ko) 에스트라무스틴 포스페이트와 아미노산을 포함하는비경구용 조성물
EP4000628B1 (en) Composition and method for vancomycin oral liquid
JP4456177B2 (ja) 注射剤、注射液および注射用キット製剤
CA2700263A1 (en) Soluble dosage forms containing cephem derivatives suitable for parenteral administration
CN111465389B (zh) 多西他赛共缀物的药物组合物及制备方法
WO2006004028A1 (ja) キノロン含有医薬組成物
HK40073481A (en) Rifabutin compositions and method of making
HK40073481B (en) Rifabutin compositions and method of making
KR20240154544A (ko) 도세탁셀 조성물 및 방법
CN101559037B (zh) 用于静脉和脑内注射的两元溶液型制剂
WO2009103209A1 (zh) 一种稳定的s-(-)-那氟沙星l-精氨酸盐组合物、其制备方法及用途
EP4135686A1 (en) Basic chemotherapeutic intratumour injection formulation
WO2026105164A1 (en) Non-aqueous liquid formulations of tetracycline antibiotics
KR20250070034A (ko) 오렐라닌 제제
Qi et al. P1381 Pharmacokinetics of teicoplanin in Chinese patients undergoing CAPD

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination